Molecular Partners AG income statement

In fiscal 2025, Molecular Partners AG reported revenue of $0, down 100.0% on the year before and net income of −$74.4m, or −$1.99 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Molecular Partners AG: income statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	21	10	11	199	8	6	0
Research and development	44	60	61	53	54	55	49
Operating income	−37	−62	−69	122	−68	−70	−70
Interest expense	0	0	0	0	0	0	0
Income before tax	−37	−67	−70	124	−69	−61	−74
Income tax	0	−0	0	0	0	0	0
Net income	−37	−67	−70	124	−69	−61	−74
Diluted EPS	−$1.70	−$2.68	−$2.25	$3.71	−$2.10	−$1.81	−$1.99
Diluted shares (average)	21m	25m	31m	33m	33m	34m	37m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Molecular Partners AG's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Molecular Partners AG.